Neumora Therapeutics Inc
NMRA1.780USD
-0.030-1.66%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
288.27MMarket Cap
LossP/E TTM
More Details of Neumora Therapeutics Inc Company
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Inc Info
Ticker SymbolNMRA
Company nameNeumora Therapeutics Inc
IPO dateSep 15, 2023
CEOBerns (Paul L)
Number of employees110
Security typeOrdinary Share
Fiscal year-endSep 15
Address260 Arsenal Place, Suite 1
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone18577600900
Websitehttps://neumoratx.com/
Ticker SymbolNMRA
IPO dateSep 15, 2023
CEOBerns (Paul L)
Company Executives of Neumora Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Amgen Inc
21.46%
ARCH Venture Partners
20.54%
Berns (Paul L)
4.66%
SB Global Advisers Ltd
3.97%
MIC Capital Management UK LLP
2.71%
Other
46.66%
Shareholders
Shareholders
Proportion
Amgen Inc
21.46%
ARCH Venture Partners
20.54%
Berns (Paul L)
4.66%
SB Global Advisers Ltd
3.97%
MIC Capital Management UK LLP
2.71%
Other
46.66%
Shareholder Types
Shareholders
Proportion
Venture Capital
21.66%
Investment Advisor
21.51%
Corporation
21.46%
Individual Investor
5.33%
Hedge Fund
3.79%
Investment Advisor/Hedge Fund
2.35%
Endowment Fund
2.01%
Research Firm
0.63%
Bank and Trust
0.03%
Other
21.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
293
86.79M
53.64%
-40.47M
2025Q2
288
142.02M
87.70%
-25.57M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
2023Q3
54
110.63M
71.42%
+110.63M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Amgen Inc
35.37M
21.84%
--
--
Apr 10, 2025
ARCH Venture Partners
31.93M
19.72%
--
--
Nov 12, 2024
Berns (Paul L)
7.68M
4.74%
+242.77K
+3.27%
Apr 10, 2025
SB Global Advisers Ltd
6.54M
4.04%
--
--
Jun 30, 2025
MIC Capital Management UK LLP
2.23M
1.38%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
4.36M
2.69%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
4.76M
2.94%
-562.13K
-10.56%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.50M
2.16%
+6.35K
+0.18%
Jun 30, 2025
Wellcome Trust
3.31M
2.04%
--
--
Jun 30, 2025
ICONIQ Capital, LLC
2.56M
1.58%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Schwab U.S. Broad Market ETF
0%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0%
iShares US Small-Cap Equity Factor ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neumora Therapeutics Inc?
The top five shareholders of Neumora Therapeutics Inc are:
Amgen Inc holds 35.37M shares, accounting for 21.84% of the total shares.
ARCH Venture Partners holds 31.93M shares, accounting for 19.72% of the total shares.
Berns (Paul L) holds 7.68M shares, accounting for 4.74% of the total shares.
SB Global Advisers Ltd holds 6.54M shares, accounting for 4.04% of the total shares.
MIC Capital Management UK LLP holds 2.23M shares, accounting for 1.38% of the total shares.
Amgen Inc holds 35.37M shares, accounting for 21.84% of the total shares.
ARCH Venture Partners holds 31.93M shares, accounting for 19.72% of the total shares.
Berns (Paul L) holds 7.68M shares, accounting for 4.74% of the total shares.
SB Global Advisers Ltd holds 6.54M shares, accounting for 4.04% of the total shares.
MIC Capital Management UK LLP holds 2.23M shares, accounting for 1.38% of the total shares.
What are the top three shareholder types of Neumora Therapeutics Inc?
The top three shareholder types of Neumora Therapeutics Inc are:
Amgen Inc
ARCH Venture Partners
Berns (Paul L)
Amgen Inc
ARCH Venture Partners
Berns (Paul L)
How many institutions hold shares of Neumora Therapeutics Inc (NMRA)?
As of 2025Q3, 293 institutions hold shares of Neumora Therapeutics Inc, with a combined market value of approximately 86.79M, accounting for 53.64% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.06%.
What is the biggest source of revenue for Neumora Therapeutics Inc?
In --, the -- business generated the highest revenue for Neumora Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
